AR118650A1 - Rendimiento mejorado de formulaciones sólidas y solubilizadas amorfas para lograr concentraciones de plasma terapéuticas - Google Patents

Rendimiento mejorado de formulaciones sólidas y solubilizadas amorfas para lograr concentraciones de plasma terapéuticas

Info

Publication number
AR118650A1
AR118650A1 ARP200101025A ARP200101025A AR118650A1 AR 118650 A1 AR118650 A1 AR 118650A1 AR P200101025 A ARP200101025 A AR P200101025A AR P200101025 A ARP200101025 A AR P200101025A AR 118650 A1 AR118650 A1 AR 118650A1
Authority
AR
Argentina
Prior art keywords
solubilized
formulations
amorphas
plasma concentrations
enhanced performance
Prior art date
Application number
ARP200101025A
Other languages
English (en)
Inventor
Narayan Swamy Panduranga
Roopa Narasimhamurthy
Shabeerali Pattasseri
Sharmistha Pal
Gajendra Singh Chowan
Srikanth Koravady Sridhar
Ajay Saxena
Theresa M Ziemba
Vrushali M Waknis
Kevin J Stefanski
Jay Poorna Reddy
Jaquan Kalani Levons
Robert J Garmise
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR118650A1 publication Critical patent/AR118650A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta se refiere a dispersiones sólidas amorfas que comprenden el Compuesto (I) que tiene la fórmula (1) y uno o más polímeros o formulaciones de solución que comprenden el Compuesto (I) y uno o más codisolventes y tensioactivos. Las formulaciones exhiben una mayor estabilidad y biodisponibilidad.
ARP200101025A 2019-04-11 2020-04-13 Rendimiento mejorado de formulaciones sólidas y solubilizadas amorfas para lograr concentraciones de plasma terapéuticas AR118650A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962832606P 2019-04-11 2019-04-11

Publications (1)

Publication Number Publication Date
AR118650A1 true AR118650A1 (es) 2021-10-20

Family

ID=70465560

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101025A AR118650A1 (es) 2019-04-11 2020-04-13 Rendimiento mejorado de formulaciones sólidas y solubilizadas amorfas para lograr concentraciones de plasma terapéuticas

Country Status (18)

Country Link
US (1) US20220144835A1 (es)
EP (1) EP3953355A1 (es)
JP (1) JP2022526656A (es)
KR (1) KR20210151183A (es)
CN (1) CN113924300A (es)
AR (1) AR118650A1 (es)
AU (1) AU2020271103A1 (es)
BR (1) BR112021020257A2 (es)
CA (1) CA3132530A1 (es)
CL (1) CL2021002627A1 (es)
CO (1) CO2021015054A2 (es)
EA (1) EA202192753A1 (es)
IL (1) IL287103A (es)
MX (1) MX2021012288A (es)
PE (1) PE20212367A1 (es)
SG (1) SG11202111131VA (es)
TW (1) TW202104228A (es)
WO (1) WO2020210629A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023010629A (es) 2021-03-09 2023-09-19 Bayer Ag Formas de dosificacion farmaceuticas que comprenden (4s)-24-cloro-4-etil-7?-fluoro-35-metoxi-3?,5-dioxo-14-(trifluoro metil)-3?h-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola-2(1,2),7(1) -dibencenaheptafano-74-carboxamida.
EP4401736A1 (en) 2021-09-17 2024-07-24 Bristol-Myers Squibb Company Milvexian for prevention and treatment of thromboembolic disorders
WO2024030409A1 (en) 2022-08-01 2024-02-08 Bristol-Myers Squibb Company Use of milvexian for treating or preventing ischemic stroke
WO2024167899A1 (en) 2023-02-06 2024-08-15 Bristol-Myers Squibb Company Milvexian pharmaceutical compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK569786A (da) 1985-11-27 1987-05-28 Syntex Inc Benzimidazolderivater
DK0901786T3 (da) 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
WO2010102245A1 (en) 2009-03-05 2010-09-10 Upsher-Smith Laboratories, Inc. Solid dispersion comprising resveratrol
JP6464176B2 (ja) * 2014-01-31 2019-02-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 芳香族ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環
NO2721243T3 (es) * 2014-10-01 2018-10-20
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors

Also Published As

Publication number Publication date
PE20212367A1 (es) 2021-12-21
AU2020271103A1 (en) 2021-12-02
US20220144835A1 (en) 2022-05-12
IL287103A (en) 2021-12-01
CO2021015054A2 (es) 2021-11-19
EP3953355A1 (en) 2022-02-16
WO2020210629A1 (en) 2020-10-15
CN113924300A (zh) 2022-01-11
KR20210151183A (ko) 2021-12-13
JP2022526656A (ja) 2022-05-25
MX2021012288A (es) 2021-11-12
TW202104228A (zh) 2021-02-01
EA202192753A1 (ru) 2022-01-11
BR112021020257A2 (pt) 2021-12-07
SG11202111131VA (en) 2021-11-29
CA3132530A1 (en) 2020-10-15
CL2021002627A1 (es) 2022-05-06

Similar Documents

Publication Publication Date Title
AR118650A1 (es) Rendimiento mejorado de formulaciones sólidas y solubilizadas amorfas para lograr concentraciones de plasma terapéuticas
CO2022002634A2 (es) Formas cristalinas de moduladores del cftr
DOP2018000241A (es) Derivados aromáticos de sulfonamida
CY1119488T1 (el) Παραγων για θεραπεια ή/και αποτροπη διαταραχης υπνου
UY35362A (es) Compuestos terapéuticos
CO2018007669A2 (es) Pirimidinas sustituidas con arilo para su uso en la infección por virus influenza
UY35300A (es) Formulación de combinación de dos compuestos antivirales
HN2012001162A (es) Triazolopiridinas
ECSP12011684A (es) Inhibidores de los virus flaviviridae.
RS53209B (en) PHARMACEUTICAL COMPOSITION FOR VIRAL HEPATITIS C PROTEASE INHIBITOR
AR099632A1 (es) Tratamiento de una infección viral de hepatitis c, que usa una combinación de compuestos
DE602008004356D1 (de) Konservierungsmittelfreie augenlösung auf prostaglandin-basis
CL2012001583A1 (es) Preparación oftálmica que comprende: a) povidona yodada, b) un agente refrescante y c) uno o más entre alcanfor, borneol, lubricante, emoliente, antiinflamatorio esteroidal y antinflamatorio no esteroidal; y su uso para el tratamiento y/o profilaxis de un trastorno ocular o una infección.
CU24525B1 (es) Derivado de quinoleína para tratar y prevenir infecciones virales
UY33885A (es) Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes
CO2021007453A2 (es) Conjugados de insulina
CL2023000524A1 (es) Compuestos fosfolípidos y usos de los mismos
CL2022001741A1 (es) Compuestos cíclicos y métodos de uso de estos
CO2019003632A2 (es) Formulaciones de buprenorfina de liberación sostenida
CU20200100A7 (es) Compuestos 3-ciano n-sustituidos de hidrotienopiridina útiles para prevenir y tratar las infecciones virales, especialmente dengue, y composiciones farmacéuticas que los contienen
ECSP23088732A (es) Moduladores de trex1
CL2018001408A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
AR109407A1 (es) Compuesto de 1-acetil-3-fenilurea y su uso
AR109409A1 (es) Compuesto de 3-piridiloxifenildihidrouracilo y su uso
CL2022001314A1 (es) Fármaco para el tratamiento o la prevención de la hemorragia cerebral, y método para el tratamiento o la prevención de la hemorragia cerebral con dicho fármaco